New nurse-led program aims to help breast cancer survivors overcome hormone therapy hesitation
NCT ID NCT05465408
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a brief, nurse-led videoconference program designed to help breast cancer survivors who were hesitant or delayed in starting recommended hormone therapy. The program aimed to address cultural and personal concerns. Researchers measured how many people enrolled, completed sessions, and reported satisfaction. The goal was to see if this approach is feasible and acceptable, not yet to prove it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Culturally aware behavioral intervention (nurse-led videoconference sessions)
What this could lead to
If successful, this approach could help more breast cancer survivors start and stick with hormone therapy, potentially improving long-term outcomes.
What could go wrong
This is a small, early feasibility study with only 35 participants. It does not prove the intervention works on a large scale or improves survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Brigham Cancer Center - Foxborough
Foxborough, Massachusetts, 02035, United States
-
Dana-Farber Brigham Cancer Center at Milford Regional Medical Center
Milford, Massachusetts, 01757, United States
-
Dana-Farber Brigham Cancer Center with South Shore Hospital
Weymouth, Massachusetts, 02190, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Dana-Farber Cancer Institute - Merrimack Valley
Methuen, Massachusetts, 01844, United States
-
Dana-Farber Cancer Institute at St Elizabeth's Medical Center
Brighton, Massachusetts, 02135, United States
-
Dana-Farber/New Hampshire Onoclogy-Hematology
Londonderry, New Hampshire, 03053, United States
-
Emerson Hospital/MGH Cancer Center
Concord, Massachusetts, 01742, United States
-
Mass General at Newton Wellesley Hospital
Newton, Massachusetts, 02462, United States
-
Mass General at North Shore Cancer Center
Danvers, Massachusetts, 01923, United States
-
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114, United States